Mylet Johanna 4
4 · Poseida Therapeutics, Inc. · Filed Mar 4, 2024
Insider Transaction Report
Form 4
Mylet Johanna
Chief Financial Officer
Transactions
- Award
Common Stock
2024-03-01+80,743→ 264,374 total - Award
Employee Stock Option (Right to Buy)
2024-03-01+111,700→ 111,700 totalExercise: $4.13Exp: 2034-02-28→ Common Stock (111,700 underlying) - Tax Payment
Common Stock
2024-03-01$4.13/sh−18,091$74,716→ 246,283 total
Footnotes (4)
- [F1]Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
- [F2]Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023.
- [F3]Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023.
- [F4]12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.